


Psoriasis and COVID



<http://www.psoprotect.org>

[HOME](#)

[REPORT A CASE](#)

[CURRENT DATA](#)

[PUBLICATIONS](#)

[PARTNERS](#)

[FAQS](#)

[CONTACT](#)



PsoProtect

Welcome to PsoProtect. We are the Psoriasis Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection.

PsoProtect is an international registry for health care providers to report outcomes of COVID-19 in individuals with psoriasis.

We are incredibly grateful for your important contribution to this international effort. Please report your cases of COVID-19 in psoriasis using the [PsoProtect case report form](#), which collects de-identified data and takes approximately 5 minutes to complete. You will be provided with a copy of your completed case report form upon submission.

The information you provide will rapidly inform clinicians when assessing risk and treating COVID-19 in patients with psoriasis and other immune-mediated inflammatory diseases. It will help improve our understanding of how factors such as immunomodulator therapies and comorbidities affect outcomes of COVID-19 in psoriasis.

We will provide regular, open access [summaries](#) of all reported cases in PsoProtect, for the benefit of the international psoriasis community.

Thank you,

Dr. Satveer Mahil, Prof. Chris Griffiths, Prof. Jonathan Barker and Prof. Catherine Smith

On behalf of the [PsoProtect steering committee](#).

UPDATES

 25

Partners

 88

Countries

More information about our
partners [here](#).

Current Data

We are committed to sharing data and are delighted to provide open access to summary data of the cases in PsoProtect. These data are preliminary and include a limited number of cases, so should not be used to inform clinical decision making.

Click [here](#) to read our recently published scientific research paper detailing the PsoProtect data, entitled **'Factors associated with adverse COVID-19 outcomes in patients with psoriasis – insights from a global registry-based study'**.

770

Total number of cases reported

Summary data from PsoProtect's first 666 cases.

Cases reported by country of assessment (≥ 20 cases):

Country	Cases
United Kingdom	206
Italy	114
Spain	86
France	70
Portugal	36
Netherlands	32
United States	30
Rest of the world	92

Average age: **50 years**

Phenotype of psoriasis: **650 plaque psoriasis, 16 pustular psoriasis**

Average BMI: **27.3 kg/m²**


Average number of days of symptoms from COVID-19: **12 days**



PsoProtect

www.psoprotect.org

Impact of COVID-19 in People with Psoriasis Taking Drugs that Affect the Immune System: Findings from the PsoProtect Registry



Study Population:
374 patients with psoriasis and COVID-19 reported to PsoProtect from 25 countries

Hospitalized for COVID-19

Overall Outcomes of COVID-19



PsoProtect
www.psoprotect.org

Shielding behaviour of people with psoriasis or musculoskeletal conditions in the COVID-19 pandemic: Findings from PsoProtectMe and CORE-UK

3,720 patient responses regarding their experiences through the COVID-19 pandemic

Medication Type



66% shielding

Targeted
Therapy
(e.g. Biologics)



59% shielding

Systemic
Therapy
(e.g. Methotrexate)



59% shielding

No Systemic
Therapy

How likely to shield?



People with these
characteristics were
more likely to shield



Male

14%



Joint Disease

37%



Underlying
Health
Condition

43%



Anxiety or
Depression

57%

Increased likelihood of shielding